Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 02 2020
Historique:
pubmed: 3 1 2020
medline: 20 11 2020
entrez: 3 1 2020
Statut: ppublish

Résumé

Studies on uveal melanomas (UMs) have demonstrated the prognostic value of 8q gain and monosomy 3, but the prognosis of UMs with partial deletion of chromosome 3 remains to be defined. To examine the association of partial chromosome 3 deletion in UMs with metastasis-free survival. This retrospective cohort study of 1088 consecutive comparative genomic hybridization arrays performed from May 1, 2006, to July 31, 2015, assessed patients presenting with UMs with and without partial loss of chromosome 3 at a referral center. Data analysis was performed from September 1, 2017, to November 30, 2017. Uveal melanoma with or without partial loss of chromosome 3. Metastasis-free survival and overall survival at 60 months. Of the 1088 consecutive comparative genomic hybridization arrays that were performed, 43 UMs (4.0%) in 43 patients (median age, 58 years [range, 12-79 years]; 22 [51%] female) carried partial deletions of chromosome 3. Median follow-up was 66 months (range, 1.2-126.2 months). Metastasis-free survival at 60 months was 33.6% (95% CI, 15.8%-71.4%) for UMs that carried a deletion of the BAP1 (BRCA1 associated protein 1) locus (BAP1del; 24 tumors) and 80.5% (95% CI, 64.8%-100%) for UMs without the loss of the BAP1 locus (BAP1 normal [BAP1nl]; 19 tumors) (log-rank P = .001). Overall survival at 60 months was 64.5% (95% CI, 43.5%-95.8%) in the BAP1del group vs 84.1% (95% CI, 69.0%-100%) in the BAP1nl group (log-rank P < .001). In these 43 cases, metastasis-free survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 70.0% (95% CI, 50.5%-96.9%) for UMs that carried 1 of these alterations, and 12.5% (95% CI, 2.1%-73.7%) for those that carried both (log-rank P < .001). Similarly, overall survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 80.8% (95% CI, 63.3%-100%) for UMs that carried 1 of these alterations, and 46.7% (95% CI, 23.3%-93.6%) for those that carried both (log-rank P < .001). These findings suggest that partial deletion of chromosome 3 encompassing the BAP1 locus is associated with poor prognosis. A cytogenetic classification of UMs could be proposed based on the status of the BAP1 locus instead of the chromosome 3 locus, while also taking chromosome 8q into account.

Identifiants

pubmed: 31895446
pii: 2757831
doi: 10.1001/jamaophthalmol.2019.5403
pmc: PMC6990836
doi:

Substances chimiques

BAP1 protein, human 0
Tumor Suppressor Proteins 0
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

182-188

Commentaires et corrections

Type : CommentIn

Références

Clin Cancer Res. 2016 Mar 1;22(5):1234-42
pubmed: 26933176
Oncotarget. 2016 Jan 26;7(4):4624-31
pubmed: 26683228
J Fr Ophtalmol. 2006 Sep;29(7):741-9
pubmed: 16988624
Nat Rev Cancer. 2001 Nov;1(2):157-62
pubmed: 11905807
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3048-55
pubmed: 19182252
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4254-62
pubmed: 18552379
Br J Cancer. 2014 Sep 23;111(7):1373-80
pubmed: 25058347
Nat Genet. 2019 Jul;51(7):1123-1130
pubmed: 31253977
Clin Cancer Res. 2010 Dec 15;16(24):6083-92
pubmed: 20975103
Clin Ophthalmol. 2016 Oct 25;10:2113-2119
pubmed: 27822007
Clin Cancer Res. 2007 Mar 1;13(5):1466-71
pubmed: 17332290
Cancer Res. 2001 Apr 15;61(8):3439-42
pubmed: 11309305
Cancer Discov. 2013 Oct;3(10):1122-1129
pubmed: 23861464
Ophthalmology. 2011 Feb;118(2):396-401
pubmed: 20869116
Transl Vis Sci Technol. 2019 Apr 17;8(2):18
pubmed: 31024753
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416209
Immunogenetics. 2019 May;71(5-6):433-436
pubmed: 30714079
Cancer Cell. 2018 Jan 8;33(1):151
pubmed: 29316429
Clin Cancer Res. 2019 Sep 15;25(18):5513-5524
pubmed: 31227496
Genes Chromosomes Cancer. 2017 Feb;56(2):168-174
pubmed: 27718540
Lancet. 1996 May 4;347(9010):1222-5
pubmed: 8622452
Br J Cancer. 2012 Mar 13;106(6):1171-6
pubmed: 22353812
Mod Pathol. 2018 May;31(5):763-771
pubmed: 29327717
Br J Ophthalmol. 2014 Jun;98(6):769-74
pubmed: 24169649
Mod Pathol. 2011 Jul;24(7):954-62
pubmed: 21499235
Invest Ophthalmol Vis Sci. 2013 Aug 23;54(8):5721-9
pubmed: 23821189
Br J Ophthalmol. 2011 Mar;95(3):424-8
pubmed: 20881029
J Natl Cancer Inst. 1990 Nov 21;82(22):1765-9
pubmed: 2231772
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80
pubmed: 19151381
Nat Genet. 2011 Aug 28;43(10):1018-21
pubmed: 21874003
Br J Ophthalmol. 2017 Aug;101(8):1143-1146
pubmed: 28596284
Acta Ophthalmol. 2014 Sep;92(6):541-9
pubmed: 24373459
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Nat Commun. 2018 May 14;9(1):1866
pubmed: 29760383
Nat Commun. 2018 Jan 9;9(1):116
pubmed: 29317634
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
J Med Genet. 2011 Dec;48(12):856-9
pubmed: 21941004
Science. 2010 Dec 3;330(6009):1410-3
pubmed: 21051595
Br J Ophthalmol. 2017 Jan;101(1):38-44
pubmed: 27574175
Invest Ophthalmol Vis Sci. 2012 Jun 05;53(7):3331-9
pubmed: 22511634
Clin Exp Metastasis. 2005;22(2):107-13
pubmed: 16086231
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Br J Ophthalmol. 2014 Dec;98(12):1738-43
pubmed: 25147369

Auteurs

Manuel Rodrigues (M)

Unit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.

Khadija Ait Rais (K)

Department of Genetics, Institut Curie, PSL Research University, Paris, France.

Flore Salviat (F)

Department of Biometry, Institut Curie, PSL Research University, Paris, France.

Nathalie Algret (N)

Department of Biometry, Institut Curie, PSL Research University, Paris, France.

Fatoumata Simaga (F)

Department of Genetics, Institut Curie, PSL Research University, Paris, France.

Raymond Barnhill (R)

Department of Biopathology, Institut Curie, PSL Research University, Paris, France.
Faculty of Medicine, University of Paris Descartes, Paris, France.

Sophie Gardrat (S)

Unit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Department of Biopathology, Institut Curie, PSL Research University, Paris, France.

Vincent Servois (V)

Department of Medical Imaging, Institut Curie, PSL Research University, Paris, France.

Pascale Mariani (P)

Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.

Sophie Piperno-Neumann (S)

Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.

Sergio Roman-Roman (S)

Department of Translational Research, Institut Curie, PSL Research University, Paris, France.

Olivier Delattre (O)

Unit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Department of Genetics, Institut Curie, PSL Research University, Paris, France.

Nathalie Cassoux (N)

Faculty of Medicine, University of Paris Descartes, Paris, France.
Department of Ocular Oncology, Institut Curie, PSL Research University, Paris, France.

Alexia Savignoni (A)

Department of Biometry, Institut Curie, PSL Research University, Paris, France.

Marc-Henri Stern (MH)

Unit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Department of Genetics, Institut Curie, PSL Research University, Paris, France.

Gaëlle Pierron (G)

Department of Genetics, Institut Curie, PSL Research University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH